Amgen (NASDAQ:AMGN) Given “Neutral” Rating at Cantor Fitzgerald

Amgen (NASDAQ:AMGN)‘s stock had its “neutral” rating reiterated by investment analysts at Cantor Fitzgerald in a research report issued on Monday,Benzinga reports. They presently have a $350.00 price objective on the medical research company’s stock. Cantor Fitzgerald’s target price points to a potential downside of 6.45% from the stock’s previous close.

AMGN has been the subject of a number of other research reports. Mizuho increased their target price on shares of Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a research report on Tuesday, June 16th. UBS Group upped their price target on shares of Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. The Goldman Sachs Group set a $389.00 price objective on shares of Amgen in a report on Friday, June 5th. Jefferies Financial Group started coverage on shares of Amgen in a research note on Tuesday, March 10th. They set a “hold” rating and a $350.00 price objective on the stock. Finally, Piper Sandler reissued an “overweight” rating on shares of Amgen in a report on Friday, June 12th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $355.50.

Amgen Stock Performance

AMGN opened at $374.15 on Monday. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The business’s 50 day moving average is $342.43 and its 200-day moving average is $348.09. The stock has a market cap of $201.93 billion, a PE ratio of 26.04, a price-to-earnings-growth ratio of 3.68 and a beta of 0.41. Amgen has a twelve month low of $269.77 and a twelve month high of $391.29.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same period in the prior year, the company posted $4.90 EPS. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, analysts predict that Amgen will post 22.39 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.85% of the company’s stock.

Institutional Trading of Amgen

Several institutional investors and hedge funds have recently added to or reduced their stakes in AMGN. Norges Bank acquired a new position in Amgen in the fourth quarter worth approximately $2,164,162,000. Capital World Investors boosted its stake in shares of Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after acquiring an additional 4,302,237 shares in the last quarter. State Street Corp grew its holdings in shares of Amgen by 4.4% in the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after acquiring an additional 1,287,310 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Amgen by 7.8% in the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after acquiring an additional 1,035,779 shares during the last quarter. Finally, Amundi raised its position in shares of Amgen by 41.1% during the fourth quarter. Amundi now owns 3,396,945 shares of the medical research company’s stock worth $1,111,854,000 after purchasing an additional 988,856 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.